Aurinia Pharmaceuticals (AUPH) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Aurinia Pharmaceuticals published the results on October 30, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Aurinia Pharmaceuticals released its remaining valuation allowance on deferred tax assets in Q4 2025, which lifted Q4 2025 diluted EPS to $1.53. From 2026 it records income tax expense near the statutory rate, so Q3 2026 net income is flat on a 21% rise in pre-tax income.
• Aurinia completed its acquisition of Kezar Life Sciences on May 11, 2026, for $6.955 in cash per Kezar share plus one contingent value right.

Source: Aurinia Pharmaceuticals Q3 2026 results, October 30, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Aurinia Pharmaceuticals splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Aurinia Pharmaceuticals's Net product sales (LUPKYNIS) revenue was $79.4 million in Q3 2026, up 12% from $70.6 million in Q3 2025, 95% of total revenue.
• Aurinia Pharmaceuticals's License, collaboration and royalty revenue revenue was $4.3 million in Q3 2026, up 51% from $2.8 million in Q3 2025, 5% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Aurinia Pharmaceuticals said:

“Aurinia is increasing its total revenue guidance for 2026 from a range of $315 million to $325 million to a range of $325 million to $330 million.”

“Aurinia is narrowing its net product sales guidance for 2026 from a range of $305 million to $315 million to a range of $310 million to $315 million.”

Source: Aurinia Pharmaceuticals Q3 2026 release, Oct 30, 2026.

This is the company's own guidance as of Oct 30, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the AUPH forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP total revenue and diluted EPS, each as first reported in that quarter's release. Q4 2025 EPS includes the release of Aurinia's remaining deferred tax valuation allowance.

We do not hold a confirmed date for Aurinia Pharmaceuticals's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 30, 2026

Aurinia Pharmaceuticals is a one-product company: net product sales of LUPKYNIS (voclosporin), an oral therapy for adults with active lupus nephritis, were $79.4 million of its $83.7 million Q3 2026 revenue, up 12% from $70.6 million. Total revenue rose 14% from $73.5 million. (Aurinia Pharmaceuticals Q3 2026 release, Oct 30, 2026)

Aurinia attributed the LUPKYNIS increase mainly to more cartons sold to specialty pharmacies, driven by further lupus nephritis market penetration. In the U.S. it sells to two specialty pharmacies and a specialty distributor, and it sells LUPKYNIS inventory to its partner Otsuka for Europe and Japan; those four buyers are its customers for accounting purposes. (Aurinia Pharmaceuticals Form 10-Q, Q3 2026, Oct 30, 2026)

License, collaboration and royalty revenue, all from Otsuka, rose 54% to $4.3 million from $2.8 million, mainly from manufacturing services for sharing the capacity of the Monoplant, a dedicated voclosporin manufacturing facility at Lonza. Under the 2020 agreement Otsuka pays royalties of 10% to 20% on net sales in Japan, the E.U., the U.K. and other Otsuka Territories. (Aurinia Pharmaceuticals Form 10-Q, Q3 2026, Oct 30, 2026)

Aurinia settled patent litigation with Teva, which may launch a generic voclosporin in the U.S. no earlier than December 7, 2036 unless certain contingencies occur; Aurinia's U.S. Patent Nos. 10,286,036 and 11,622,991 expire in December 2037. Infringement actions continue against several other generic filers, including Sandoz, Hikma and Zydus. (Aurinia Pharmaceuticals Form 10-Q, Q3 2026, Oct 30, 2026)

Aurinia Pharmaceuticals earned $0.23 per diluted share in Q3 2026, the same as a year earlier, on net income of $31.7 million against $31.6 million. Income before taxes rose 21% to $38.7 million, but income tax expense was $7.0 million against $0.4 million: the effective tax rate was 18.1%, against 1.3%, because Aurinia released its remaining valuation allowance in Q4 2025 and has no unrecognized deferred tax assets left to offset tax expense. (Aurinia Pharmaceuticals Q3 2026 release, Oct 30, 2026; Aurinia Pharmaceuticals Form 10-Q, Q3 2026, Oct 30, 2026)

Aurinia reports only GAAP EPS. Research and development expense nearly doubled to $16.6 million from $8.4 million. Aurinia's pipeline is aritinercept, a dual BAFF and APRIL inhibitor now in clinical development in four potential indications, alongside PRESERVE, a Phase 4 study combining LUPKYNIS with biologics. (Aurinia Pharmaceuticals Q3 2026 release, Oct 30, 2026)

Diluted shares were 135,173 thousand, against 136,008 thousand. Over the first nine months of 2026 Aurinia repurchased 5.0 million shares for $74.9 million, partly offset by $35.9 million of net proceeds from equity awards. Share-based compensation was $8.1 million for the nine months. (Aurinia Pharmaceuticals Q3 2026 release, Oct 30, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Aurinia Pharmaceuticals gives full-year revenue guidance in its release. With Q3 2026 it raised 2026 total revenue guidance to $325 million to $330 million, from $315 million to $325 million, and narrowed net product sales guidance to $310 million to $315 million, from $305 million to $315 million. It gives no EPS guidance. (Aurinia Pharmaceuticals Q3 2026 release, Oct 30, 2026)

A consensus figure is the average of the models published by the analysts who cover Aurinia Pharmaceuticals, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Aurinia Pharmaceuticals's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning AUPH is on is AUPH a buy or a sell?, what analysts expect next is on the AUPH forecast, and what the company does is on the Aurinia Pharmaceuticals (AUPH) stock page.

Every number on this page can be traced to a document Aurinia Pharmaceuticals published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.